Start breaking tradition
Instead of an ICS/LABA, start appropriate symptomatic patients with COPD on ANORO for dual bronchodilation
ICS=inhaled corticosteroid; LABA=long‑acting beta2‑adrenergic agonist.
ANORO was studied in patients with moderate or worse COPD.
ICS=inhaled corticosteroid; LABA=long-acting beta2-adrenergic agonist.
The evidence speaks for itselfSee the Details
The 2 components work together to increase bronchodilationSee How It Works
Keep samples on handOrder Samples
Nationally, ANORO is covered without restrictions* on % of Medicare Part D and Commercial patients†
ANORO is covered without restrictions* for % of Medicare Part D and % of Commercial patients† nationally
Individual access may vary by geography and plan benefit design.
Source: Managed Markets Insight & Technology, LLC (MMIT), database as of .
*”Covered without restrictions” means reimbursement from a health plan without accompanying step edits or prior authorizations.
†"Patients" means covered lives for all Commercial and employer payer types (excluding Managed Medicaid), and covered lives enrolled in Medicare payer types as calculated by MMIT as of .
Commercial calculations do not include Indian Health Service or Department of Veterans Affairs lives.Click to see what you need to know about this formulary information
What you need to know about this formulary information:
Formulary status may vary and is subject to change. Formulary coverage does not imply clinical efficacy or safety. This is not a guarantee of partial or full coverage or payment. Consumers may be responsible for varying out-of-pocket costs based on an individual’s plan and its benefit design. Each plan administrator determines actual benefits and out-of-pocket costs per its plan’s policies. Verify coverage with plan sponsor or Centers for Medicare & Medicaid Services. Medicare Part D patients may obtain coverage for products not otherwise covered via the medical necessity process.